PL3300721T3 - Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania - Google Patents

Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania

Info

Publication number: PL3300721T3
Authority: PL; Poland
Prior art keywords: optimal; production; propylene glycol; injection devices; containing peptide
Prior art date: 2003-11-20

Application number

PL17196501T

Other languages

English (en)

Inventor

Claude Bonde

Dorthe Kot Engelund

Tina Bjeldskov Pedersen

Original Assignee

Novo Nordisk A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-20

Filing date

2004-11-18

Publication date

2019-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34609967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3300721(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-18 Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S

2019-08-30 Publication of PL3300721T3 publication Critical patent/PL3300721T3/pl

Links

DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 title 3
238000009472 formulation Methods 0.000 title 1
238000002347 injection Methods 0.000 title 1
239000007924 injection Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

PL17196501T 2003-11-20 2004-11-18 Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania PL3300721T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DKPA200301719		2003-11-20
EP17196501.5A EP3300721B2 (en)	2003-11-20	2004-11-18	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
PCT/DK2004/000792 WO2005049061A2 (en)	2003-11-20	2004-11-18	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
EP04797453.0A EP1687019B1 (en)	2003-11-20	2004-11-18	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices

Publications (1)

Publication Number	Publication Date
PL3300721T3 true PL3300721T3 (pl)	2019-08-30

Family

ID=34609967

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL17196501T PL3300721T3 (pl)	2003-11-20	2004-11-18	Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania
PL04797453T PL1687019T3 (pl)	2003-11-20	2004-11-18	Formulacje peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniach do wstrzykiwań

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL04797453T PL1687019T3 (pl)	2003-11-20	2004-11-18	Formulacje peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniach do wstrzykiwań

Country Status (20)

Country	Link
US (5)	US8114833B2 (pl)
EP (3)	EP1687019B1 (pl)
JP (2)	JP5558655B2 (pl)
KR (1)	KR101243648B1 (pl)
CN (4)	CN1882356B (pl)
AU (1)	AU2004290862B2 (pl)
BR (1)	BRPI0416743A (pl)
CA (1)	CA2545034C (pl)
CY (1)	CY1119723T1 (pl)
DK (2)	DK3300721T4 (pl)
ES (2)	ES2660320T3 (pl)
FI (1)	FI3300721T4 (pl)
HK (1)	HK1246683B (pl)
HU (2)	HUE038395T2 (pl)
MX (1)	MXPA06005581A (pl)
PL (2)	PL3300721T3 (pl)
PT (2)	PT3300721T (pl)
SI (2)	SI3300721T2 (pl)
TR (1)	TR201906789T4 (pl)
WO (1)	WO2005049061A2 (pl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5562510B2 (ja) *	2001-06-28	2014-07-30	ノヴォノルディスクアー／エス	修飾ｇｌｐ−１の安定な処方剤
PL3300721T3 (pl)	2003-11-20	2019-08-30	Novo Nordisk A/S	Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania
RU2524150C2 (ru)	2006-09-22	2014-07-27	Ново Нордиск А/С	Аналоги инсулина, устойчивые к протеазам
CN101674812B (zh)	2007-04-30	2013-12-11	诺沃-诺迪斯克有限公司	干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物
EP2164466A1 (en) *	2007-06-01	2010-03-24	Novo Nordisk A/S	Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
US20100144592A1 (en) *	2007-06-01	2010-06-10	Nove Nordisk A/S	Stable Non-Aqueous Pharmaceutical Compositions
CN101970477B (zh)	2008-03-14	2014-12-31	诺沃-诺迪斯克有限公司	蛋白酶稳定的胰岛素类似物
EP2254906B1 (en)	2008-03-18	2016-10-05	Novo Nordisk A/S	Protease stabilized, acylated insulin analogues
EP2111871A1 (de) *	2008-04-26	2009-10-28	Sandoz AG	Stabilisierte Flüssigformulierung
US8031419B2 (en)	2009-07-28	2011-10-04	Hong Kong Applied Science and Technology Research Institute, Co., Ltd.	Compact imaging device
US20110097386A1 (en) *	2009-10-22	2011-04-28	Biodel, Inc.	Stabilized glucagon solutions
US9610329B2 (en) *	2009-10-22	2017-04-04	Albireo Pharma, Inc.	Stabilized glucagon solutions
RU2529800C2 (ru)	2010-03-18	2014-09-27	ИННОФАРМА, Инк.	Стабильные составы бортезомиба
US8263578B2 (en)	2010-03-18	2012-09-11	Innopharma, Inc.	Stable bortezomib formulations
HUE036066T2 (hu)	2010-12-16	2018-06-28	Novo Nordisk As	GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
CN106117344B (zh)	2011-04-12	2020-11-03	诺沃—诺迪斯克有限公司	双酰化glp-1衍生物
RU2578460C2 (ru) *	2011-08-10	2016-03-27	Адосиа	Приемлемый для инъекций раствор по меньшей мере одного базального инсулина
RU2641198C3 (ru)	2012-03-22	2021-12-10	Ново Нордиск А/С	Композиции glp-1 пептидов и их получение
KR20150002777A (ko)	2012-04-11	2015-01-07	노보 노르디스크 에이/에스	인슐린 제제
ES2871328T3 (es)	2012-06-20	2021-10-28	Novo Nordisk As	Formulación de comprimido que comprende un péptido y un agente de suministro
RU2018117557A (ru)	2012-07-01	2019-03-22	Ново Нордиск А/С	Применение долгодействующих пептидов glp-1
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902920A (zh)	2012-12-21	2015-09-09	赛诺菲	作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
CN103893744B (zh) *	2012-12-24	2017-12-19	杭州九源基因工程有限公司	一种治疗糖尿病的药物制剂及其制备方法
TWI641381B (zh) *	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
HRP20181393T1 (hr)	2013-05-02	2018-11-02	Novo Nordisk A/S	Oralno doziranje spojeva glp-1
US9738697B2 (en)	2013-06-23	2017-08-22	Wisconsin Alumni Research Foundation	Alpha/beta-polypeptide analogs of glucagon-like peptide-1
CN104415326A (zh) *	2013-08-28	2015-03-18	深圳翰宇药业股份有限公司	一种含有利拉鲁肽的药物制剂组合物及其制备方法
AU2014333979B2 (en)	2013-10-07	2018-02-15	Novo Nordisk A/S	Novel derivative of an insulin analogue
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
CN112957455A (zh)	2014-01-09	2021-06-15	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
WO2016038521A1 (en) *	2014-09-08	2016-03-17	Sun Pharmaceutical Industries Limited	Pharmaceutical compositions of liraglutide
WO2016059593A1 (en) *	2014-10-16	2016-04-21	Piramal Enterprises Limited	Stable injectable composition of protein drugs and process for its preparation
EP3295952B1 (en) *	2015-05-13	2021-02-17	Hangzhou Jiuyuan Gene Engineering Co., Ltd	Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
EP3936143A1 (en)	2015-05-22	2022-01-12	The Board of Trustees of the Leland Stanford Junior University	Treatment of post-bariatric hypoglycemia with exendin (9-39)
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP2019506440A (ja) *	2016-03-01	2019-03-07	深▲せん▼翰宇薬業股▲ふん▼有限公司ＨｙｂｉｏＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	医薬組成物及びその製造方法
US9968659B2 (en) *	2016-03-04	2018-05-15	Novo Nordisk A/S	Liraglutide in cardiovascular conditions
MA43684A (fr) *	2016-03-04	2018-11-28	Novo Nordisk As	Liraglutide utilisé dans le traitement de maladies rénales
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017220463A1 (en) *	2016-06-20	2017-12-28	Isa Pharmaceuticals B.V.	Formulation of a peptide vaccine
US10350293B2 (en)	2016-08-23	2019-07-16	Pharmacotherapia d.o.o.	Compositions and methods for treating symptoms associated with multiple sclerosis
WO2018057977A1 (en)	2016-09-23	2018-03-29	Delpor, Inc.	Stable compositions for incretin mimetic compounds
SI3541366T1 (sl)	2016-11-21	2025-05-30	Amylyx Pharmaceuticals, Inc.	Zapufrane formulacije eksendina (9-39)
HRP20211281T1 (hr)	2016-12-16	2021-11-12	Novo Nordisk A/S	Pripravci koji sadrže inzulin
GB201621987D0 (en) *	2016-12-22	2017-02-08	Archer Virgil L See Archer Sheri A Arecor Ltd	Novel composition
ES2989204T3 (es)	2017-06-16	2024-11-25	Zealand Pharma As	Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
CA3082033A1 (en)	2017-08-24	2019-02-28	Novo Nordisk A\S	Glp-1 compositions and uses thereof
MY204827A (en)	2017-10-12	2024-09-18	Novo Nordisk As	Semaglutide in medical therapy
PE20210453A1 (es)	2018-02-02	2021-03-08	Novo Nordisk As	Composiciones solidas que comprenden un agonista de glp-1, una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante
WO2019200594A1 (zh)	2018-04-19	2019-10-24	杭州先为达生物科技有限公司	酰化的glp-1衍生物
TWI705820B (zh) *	2018-06-22	2020-10-01	美商美國禮來大藥廠	Gip/glp1促效劑組合物
EP3628682A1 (en) *	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations of glucagon-like-peptide-2 (glp-2) analogues
US11058745B1 (en)	2018-10-04	2021-07-13	Good Health, Llc	Stable liquid pharmaceutical compositions of daptomycin
KR102742007B1 (ko) *	2018-10-09	2024-12-12	유니버시티 오브 서던 캘리포니아	양이온성 마크로사이클릭 펩티드의 전신 전달성, 내약성, 및 효능을 향상시키기 위한 조성물 및 방법(compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides)
PE20211492A1 (es) *	2018-10-26	2021-08-11	Novo Nordisk As	Composiciones estables de semaglutida y usos de las mismas
EP3897570A1 (en)	2018-12-19	2021-10-27	KRKA, d.d., Novo mesto	Pharmaceutical composition comprising glp-1 analogue
US11471512B2 (en)	2019-03-01	2022-10-18	Merck Sharp & Dohme Llc	Pharmaceutical compositions of a peptide
WO2020208541A1 (en) *	2019-04-08	2020-10-15	Enzene Biosciences Limited	Composition comprising glp-1 analogue
WO2021123228A1 (en)	2019-12-18	2021-06-24	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
MX2022009844A (es)	2020-02-18	2022-09-05	Novo Nordisk As	Composiciones y usos del peptido similar al glucagon-1 (glp-1).
EP4126004A1 (en)	2020-03-30	2023-02-08	Zealand Pharma A/S	Agonist combination
US11478533B2 (en)	2020-04-27	2022-10-25	Novo Nordisk A/S	Semaglutide for use in medicine
AU2021399904B2 (en) *	2020-12-16	2024-09-05	Zealand Pharma A/S	Pharmaceutical composition of glp-1/glp-2 dual agonists
WO2022232168A1 (en)	2021-04-27	2022-11-03	Aardvark Therapeutics, Inc.	Combination of bitter receptor agonist and gut-signaling compound
KR20240126450A (ko)	2021-11-10	2024-08-20	아이투오 테라퓨틱스, 인코포레이티드	이온성 액체 조성물

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU542560B2 (en) †	1980-03-21	1985-02-28	Wellcome Foundation Limited, The	Stabilised ophthalmic solution
US4483849A (en) †	1983-01-07	1984-11-20	Carter William A	Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
US4468346A (en)	1983-10-27	1984-08-28	The United States Of America As Represented By The Secretary Of Agriculture	Monoclonal antibodies to porcine immunoglobulins
PH25772A (en)	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
EP0305387B2 (en)	1986-05-05	1996-08-28	The General Hospital Corporation	Insulinotropic hormone
DE3885459T2 (de)	1987-05-14	1994-03-24	Commw Scient Ind Res Org	Molkeproteinfraktionen.
JPH03505401A (ja)	1988-06-27	1991-11-28	ジェネックス・コーポレーション	組換えタンパク質の培養培地への熱放出
DE3837825A1 (de)	1988-11-08	1990-05-10	Hoechst Ag	Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JPH04502465A (ja)	1988-12-23	1992-05-07	ノボ　ノルディスク　アクティーゼルスカブ	ヒトインシュリン類似物質
NZ232375A (en)	1989-02-09	1992-04-28	Lilly Co Eli	Insulin analogues modified at b29
EP0464022B1 (en)	1989-03-20	2000-05-31	The General Hospital Corporation	Insulinotropic hormone
JP2822447B2 (ja) *	1989-05-19	1998-11-11	住友電気工業株式会社	酸化物超電導線材の製造方法および装置
US5216011A (en) †	1989-09-01	1993-06-01	Bristol-Myers Squibb Co.	Stable solutions of mitomycin c
DE69013471T2 (de)	1989-12-05	1995-03-30	Merck & Co Inc	Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe.
DK0512042T3 (da)	1990-01-24	1998-05-11	Douglas I Buckley	GLP-1-analoger anvendelige ved diabetesbehandling
DE4002066A1 (de)	1990-01-25	1991-08-01	Basf Ag	Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
DE69103120T2 (de) *	1990-10-26	1995-03-30	Furukawa Electric Co Ltd	Polyphenylensulfid-Zusammensetzung für Pulverbeschichtung.
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv) *	1991-05-07	1991-05-07	Tomas Moks	Peptide hormone solution
US5206219A (en) *	1991-11-25	1993-04-27	Applied Analytical Industries, Inc.	Oral compositions of proteinaceous medicaments
DK36492D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
DK39892D0 (da)	1992-03-25	1992-03-25	Bernard Thorens	Peptid
SG45449A1 (en) *	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE10199011I2 (de)	1993-06-21	2004-10-14	Novo Nordisk As	ASP-B28-Insulinkristalle.
AU7531094A (en) *	1993-08-24	1995-03-21	Novo Nordisk A/S	Protracted glp-1
US6011007A (en)	1993-09-17	2000-01-04	Novo Nordisk A/S	Acylated insulin
DE69428134T2 (de)	1993-09-17	2002-05-02	Novo Nordisk A/S, Bagsvaerd	Acyliertes insulin
GB9320782D0 (en)	1993-10-08	1993-12-01	Univ Leeds Innovations Ltd	Stabilising of proteins on solution
DK0729362T3 (da) *	1993-11-19	2000-05-08	Searle & Co	Transdermal sammensætning af N-(N-(5-(4-aminoiminomethyl)-phenyl)-1-oxypentyl)-L-alfa-aspartyl)-L-phenylalanin eller estere
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
AU1847695A (en)	1994-02-22	1995-09-04	Syntex-Synergen Neuroscience Joint Venture, The	Pharmaceutical formulations of cntf
US5652216A (en)	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
US5504188A (en)	1994-06-16	1996-04-02	Eli Lilly And Company	Preparation of stable zinc insulin analog crystals
US5574008A (en)	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
DE69532492T2 (de)	1994-08-31	2004-12-02	Mitsubishi Pharma Corp.	Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
JPH10511365A (ja)	1994-12-23	1998-11-04	ノボノルディスクアクティーゼルスカブ	遅延性ｇｌｐ−１組成物
WO1996024369A1 (en)	1995-02-06	1996-08-15	Genetics Institute, Inc.	Formulations for il-12
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
JPH11511118A (ja)	1995-06-02	1999-09-28	ノボノルディスクアクティーゼルスカブ	タンパク質溶液のＡ１／Ｆｅ処理とその後の膜濃縮
US5631347A (en)	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
KR100600457B1 (ko)	1996-06-05	2006-07-13	로셰 디아그노스틱스 게엠베하	엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제
BR9710130A (pt) *	1996-07-03	1999-08-10	Alza Corp	Formulações de peptídeos próticas não-aquosas
US5981489A (en)	1996-07-18	1999-11-09	Alza Corporation	Non-aqueous protic peptide formulations
CA2262647C (en) †	1996-08-08	2007-12-04	Amylin Pharmaceuticals, Inc.	Methods for regulating gastrointestinal motility
JPH10101696A (ja)	1996-08-08	1998-04-21	Shinotesuto:Kk	形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
ATE356830T1 (de)	1996-08-30	2007-04-15	Novo Nordisk As	Glp-1 derivate
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6384016B1 (en)	1998-03-13	2002-05-07	Novo Nordisk A/S	Stabilized aqueous peptide solutions
DE122007000044I2 (de)	1997-01-07	2011-05-05	Amylin Pharmaceuticals Inc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
RU2180218C2 (ru)	1997-01-20	2002-03-10	Джапэн Энерджи Корпорейшн	Способ стабилизации гирудина и/или вариантов гирудина, лиофилизированная фармацевтическая композиция, полученная с применением данного способа
WO1998043658A1 (en)	1997-03-31	1998-10-08	Eli Lilly And Company	Glucagon-like peptide-1 analogs
CA2236519C (en)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
AR012894A1 (es)	1997-06-13	2000-11-22	Lilly Co Eli	Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
EP1036561A1 (en)	1997-10-01	2000-09-20	Flemington Pharmaceutical Corporation	Buccal, non-polar spray
WO1999021889A1 (en)	1997-10-24	1999-05-06	Genentech, Inc.	Purification of molecules
JP2001525371A (ja)	1997-12-05	2001-12-11	イーライ・リリー・アンド・カンパニー	Ｇｌｐ−１製剤
ZA9811127B (en) †	1997-12-09	2000-07-11	Lilly Co Eli	Stabilized teriparatide solutions.
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
JP2002512175A (ja)	1998-02-27	2002-04-23	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ−１類似体の誘導体類
EP1056775B1 (en)	1998-02-27	2010-04-28	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043707A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	N-terminally modified glp-1 derivatives
AU2610799A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
EP1056774A1 (en)	1998-02-27	2000-12-06	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
JP2002524514A (ja)	1998-09-17	2002-08-06	イーライ・リリー・アンド・カンパニー	タンパク質製剤
DK1140148T3 (da)	1998-12-22	2006-01-30	Lilly Co Eli	Lagerholdbar formulering af glucagon-agtigt peptid-1
AU777564B2 (en)	1999-01-14	2004-10-21	Amylin Pharmaceuticals, Inc.	Novel exendin agonist formulations and methods of administration thereof
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
EP1956000B1 (en)	1999-03-17	2016-10-05	Novo Nordisk A/S	Acylating agents useful for acylating peptides
EP1196189A2 (en)	1999-06-25	2002-04-17	Medtronic MiniMed, Inc.	Multiple agent diabetes therapy
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
WO2001021198A1 (en) †	1999-09-20	2001-03-29	Eli Lilly And Company	Method for reducing the risk of cancer
ATE288765T1 (de)	1999-12-16	2005-02-15	Lilly Co Eli	Polypeptidzusammensetzungen mit verbesserter stabilität
US7022674B2 (en)	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
US20010012829A1 (en) *	2000-01-11	2001-08-09	Keith Anderson	Transepithelial delivery GLP-1 derivatives
EP1250126A2 (en)	2000-01-11	2002-10-23	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
AU2001220765A1 (en)	2000-01-24	2001-07-31	Medtronic Minimed, Inc.	Mixed buffer system for stabilizing polypeptide formulations
DE60102899T2 (de)	2000-01-27	2005-03-31	Eli Lilly And Co., Indianapolis	Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen
EP1396499A3 (en)	2000-01-27	2004-12-29	Eli Lilly And Company	Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
US6569901B2 (en) *	2000-01-28	2003-05-27	Novo Nordisk A/S	Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en)	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
WO2001077141A1 (en)	2000-04-06	2001-10-18	Novo Nordisk A/S	Shock heat treatment of polypeptides
EA008837B1 (ru)	2000-06-16	2007-08-31	Эли Лилли Энд Компани	Аналоги глюкагоноподобного пептида и их применение
JP4798833B2 (ja)	2000-10-24	2011-10-19	一般財団法人化学及血清療法研究所	加熱処理工程を含むヒト血清アルブミンの製造方法
HU229218B1 (en)	2000-12-07	2013-09-30	Lilly Co Eli	Glp-1 fusion proteins
WO2002048192A2 (en)	2000-12-13	2002-06-20	Eli Lilly And Company	Amidated glucagon-like peptide-1
AU2002239384B2 (en)	2000-12-13	2007-01-11	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
US20020151467A1 (en) *	2000-12-21	2002-10-17	Leung Frank K.	Methods and compositions for oral insulin delivery
GB2371227A (en) *	2001-01-10	2002-07-24	Grandis Biotech Gmbh	Crystallisation - resistant aqueous growth hormone formulations
EP1360202B1 (en)	2001-02-16	2008-05-21	ConjuChem Biotechnologies Inc.	Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US6573237B2 (en)	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
AU2002257076A1 (en) *	2001-03-19	2002-10-03	President And Fellows Of Harvard College	Nucleic acid shuffling
US20040156835A1 (en)	2001-05-30	2004-08-12	Taiji Imoto	Protein preparation
JP5562510B2 (ja) *	2001-06-28	2014-07-30	ノヴォノルディスクアー／エス	修飾ｇｌｐ−１の安定な処方剤
US6872705B2 (en) †	2001-07-13	2005-03-29	Allergan, Inc.	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
CN1335182A (zh) *	2001-08-08	2002-02-13	华中科技大学	胰岛素口腔喷剂及其制备工艺
US7238663B2 (en)	2001-08-28	2007-07-03	Eli Lilly And Company	Pre-mixes of GLP-1 and basal insulin
IL160917A0 (en)	2001-10-18	2004-08-31	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2005508360A (ja)	2001-10-19	2005-03-31	イーライ・リリー・アンド・カンパニー	Ｇｌｐ−１およびインスリンの二相混合物
US7462596B2 (en)	2002-03-15	2008-12-09	Natimmune A/S	Pharmaceutical compositions comprising mannose binding lectin
AU2003226913A1 (en)	2002-04-04	2003-10-20	Novo Nordisk A/S	Glp-1 agonist and cardiovascular complications
ATE397620T1 (de)	2002-09-25	2008-06-15	Novo Nordisk As	Aufreinigungsverfahren, das eine mikrofiltration bei erhöhten temperaturen beinhaltet
US6969702B2 (en)	2002-11-20	2005-11-29	Neuronova Ab	Compounds and methods for increasing neurogenesis
WO2004089985A1 (en) *	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
WO2005000222A2 (en)	2003-05-30	2005-01-06	Amylin Pharmaceuticals, Inc.	Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
KR101293507B1 (ko)	2003-06-03	2013-08-06	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
US20060287221A1 (en) *	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
ATE525083T1 (de) *	2003-11-13	2011-10-15	Novo Nordisk As	Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
PL3300721T3 (pl) *	2003-11-20	2019-08-30	Novo Nordisk A/S	Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania
US20060286129A1 (en) *	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
US20090011976A1 (en) *	2004-11-12	2009-01-08	Novo Nordisk A/S	Stable Formulations Of Peptides
GB0704846D0 (en) *	2007-03-13	2007-04-18	Futura Medical Dev Ltd	Topical pharmaceutical formulation
BR112013019732B1 (pt) *	2011-02-04	2023-01-24	Infirst Healthcare Limited	Composição farmacêutica e seu uso no tratamento de doenças cardiovasculares
CN102579350B (zh) *	2012-03-02	2013-04-24	海南灵康制药有限公司	右旋布洛芬脂质体固体制剂

2004
- 2004-11-18 PL PL17196501T patent/PL3300721T3/pl unknown
- 2004-11-18 PT PT17196501T patent/PT3300721T/pt unknown
- 2004-11-18 EP EP04797453.0A patent/EP1687019B1/en not_active Expired - Lifetime
- 2004-11-18 HU HUE04797453A patent/HUE038395T2/hu unknown
- 2004-11-18 TR TR2019/06789T patent/TR201906789T4/tr unknown
- 2004-11-18 PT PT47974530T patent/PT1687019T/pt unknown
- 2004-11-18 CN CN200480034152.8A patent/CN1882356B/zh not_active Expired - Fee Related
- 2004-11-18 CN CN202110402074.8A patent/CN113304250A/zh not_active Withdrawn
- 2004-11-18 SI SI200432469T patent/SI3300721T2/sl unknown
- 2004-11-18 ES ES04797453.0T patent/ES2660320T3/es not_active Expired - Lifetime
- 2004-11-18 DK DK17196501.5T patent/DK3300721T4/da active
- 2004-11-18 CA CA2545034A patent/CA2545034C/en not_active Expired - Fee Related
- 2004-11-18 FI FIEP17196501.5T patent/FI3300721T4/fi active
- 2004-11-18 KR KR1020067009738A patent/KR101243648B1/ko not_active Expired - Lifetime
- 2004-11-18 BR BRPI0416743-0A patent/BRPI0416743A/pt not_active Application Discontinuation
- 2004-11-18 EP EP11157594.0A patent/EP2394656B1/en not_active Expired - Lifetime
- 2004-11-18 JP JP2006540168A patent/JP5558655B2/ja not_active Expired - Lifetime
- 2004-11-18 CN CN2012102947168A patent/CN102784386A/zh active Pending
- 2004-11-18 PL PL04797453T patent/PL1687019T3/pl unknown
- 2004-11-18 MX MXPA06005581A patent/MXPA06005581A/es active IP Right Grant
- 2004-11-18 EP EP17196501.5A patent/EP3300721B2/en not_active Expired - Lifetime
- 2004-11-18 DK DK04797453.0T patent/DK1687019T3/en active
- 2004-11-18 CN CN201510078513.9A patent/CN104826116A/zh active Pending
- 2004-11-18 WO PCT/DK2004/000792 patent/WO2005049061A2/en active Application Filing
- 2004-11-18 AU AU2004290862A patent/AU2004290862B2/en active Active
- 2004-11-18 SI SI200432419T patent/SI1687019T1/en unknown
- 2004-11-18 HU HUE17196501A patent/HUE043210T2/hu unknown
- 2004-11-18 ES ES17196501T patent/ES2727854T5/es not_active Expired - Lifetime
2006
- 2006-05-17 US US11/435,977 patent/US8114833B2/en active Active
2012
- 2012-01-31 US US13/362,745 patent/US20120225810A1/en not_active Abandoned
- 2012-03-29 JP JP2012077335A patent/JP5670373B2/ja not_active Expired - Lifetime
2018
- 2018-01-03 CY CY20181100004T patent/CY1119723T1/el unknown
- 2018-05-16 HK HK18106312.8A patent/HK1246683B/en active IP Right Maintenance
2019
- 2019-01-29 US US16/260,204 patent/US20190231876A1/en not_active Abandoned
2020
- 2020-06-24 US US16/910,945 patent/US20200316204A1/en not_active Abandoned
2022
- 2022-12-09 US US18/078,518 patent/US20230364241A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2005049061A2 (en)	2005-06-02
ES2727854T3 (es)	2019-10-21
CN113304250A (zh)	2021-08-27
ES2660320T3 (es)	2018-03-21
JP5558655B2 (ja)	2014-07-23
CN1882356B (zh)	2015-02-25
CN102784386A (zh)	2012-11-21
MXPA06005581A (es)	2006-08-11
CY1119723T1 (el)	2018-06-27
EP3300721B2 (en)	2025-01-08
JP2012188424A (ja)	2012-10-04
JP5670373B2 (ja)	2015-02-18
SI1687019T1 (en)	2018-04-30
HUE038395T2 (hu)	2018-10-29
PL1687019T3 (pl)	2018-05-30
BRPI0416743A (pt)	2007-01-16
KR101243648B1 (ko)	2013-03-14
US20190231876A1 (en)	2019-08-01
EP1687019B1 (en)	2017-11-22
US20200316204A1 (en)	2020-10-08
EP3300721B1 (en)	2019-03-06
RU2006116414A (ru)	2007-12-27
AU2004290862A1 (en)	2005-06-02
JP2007513084A (ja)	2007-05-24
DK3300721T3 (da)	2019-05-27
US20230364241A1 (en)	2023-11-16
PT3300721T (pt)	2019-06-06
WO2005049061A3 (en)	2005-10-20
AU2004290862B2 (en)	2010-06-03
DK1687019T3 (en)	2018-02-12
EP2394656A3 (en)	2012-01-18
EP2394656B1 (en)	2023-12-13
SI3300721T2 (sl)	2025-05-30
US8114833B2 (en)	2012-02-14
HK1246683B (en)	2019-11-15
TR201906789T4 (tr)	2019-05-21
PT1687019T (pt)	2018-02-26
CN1882356A (zh)	2006-12-20
WO2005049061A8 (en)	2005-12-01
US20120225810A1 (en)	2012-09-06
ES2727854T5 (en)	2025-03-24
DK3300721T4 (da)	2025-03-03
HUE043210T2 (hu)	2019-08-28
CN104826116A (zh)	2015-08-12
FI3300721T4 (fi)	2025-01-27
CA2545034A1 (en)	2005-06-02
CA2545034C (en)	2013-03-05
EP3300721A1 (en)	2018-04-04
US20070010424A1 (en)	2007-01-11
KR20060100428A (ko)	2006-09-20
EP2394656A2 (en)	2011-12-14
SI3300721T1 (sl)	2019-07-31
RU2421238C2 (ru)	2011-06-20
EP1687019A2 (en)	2006-08-09

Publication	Publication Date	Title
HUE038395T2 (hu)	2018-10-29	Propilén-glikol tartalmú peptidkészítmények, amelyek elõállításra és injekciós eszközökben történõ alkalmazásra optimálisak
IL176006A0 (en)	2006-10-05	Immunogenic peptide carrier conjugates and methods for producing the same
IL162642A0 (en)	2005-11-20	Formulations
IL164519A0 (en)	2005-12-18	Pharmaceutical formulations
IL174131A0 (en)	2006-08-01	Improvements in vaccination
GB0302671D0 (en)	2003-03-12	Pharmaceutical formulations
AU2003239248A8 (en)	2003-12-22	Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins
IL172824A0 (en)	2006-06-11	Pharmaceutical formulations
GB2392093B (en)	2006-03-08	Pharmaceutical formulations
GB0324265D0 (en)	2003-11-19	Peptide
GB0302672D0 (en)	2003-03-12	Pharmaceutical formulations
GB0313355D0 (en)	2003-07-16	Nozzle
AU2003228863A8 (en)	2003-11-17	Immunogenic peptides
AU156880S (en)	2004-11-15	Nozzle
GB0307765D0 (en)	2003-05-07	Tissue-adhesive formulations
EP1549291A4 (en)	2008-08-20	INJECTION FORMULATION
GB0305890D0 (en)	2003-04-16	Active alignment technique
GB0317376D0 (en)	2003-08-27	Immunogenic protein and uses thereof
GB0311936D0 (en)	2003-06-25	Improvements in devices
EP1699809A4 (en)	2009-10-21	PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF
GB0213005D0 (en)	2002-07-17	Injection nozzle
TW563410U (en)	2003-11-21	Combining plastic blocks used in gardens
EP1551330A4 (en)	2005-07-13	IMPROVEMENTS IN THE TECHNOLOGY OF THE CONTRIBUTION
GB0315664D0 (en)	2003-08-13	Nozzle arrangements
TW580950U (en)	2004-03-21	Improved nozzle head structure for use in horticulture